- Home
- HHS vs CTXR Comparison
HHS vs CTXR Comparison
Compare HHS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- CTXR
- Stock Information
- Founded
- HHS 1923
- CTXR 2007
- Country
- HHS United States
- CTXR United States
- Employees
- HHS N/A
- CTXR N/A
- Industry
- HHS Advertising
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- CTXR Health Care
- Exchange
- HHS Nasdaq
- CTXR Nasdaq
- Market Cap
- HHS 27.3M
- CTXR 23.0M
- IPO Year
- HHS N/A
- CTXR N/A
- Fundamental
- Price
- HHS $3.64
- CTXR $1.29
- Analyst Decision
- HHS
- CTXR Strong Buy
- Analyst Count
- HHS 0
- CTXR 3
- Target Price
- HHS N/A
- CTXR $53.00
- AVG Volume (30 Days)
- HHS 9.2K
- CTXR 450.0K
- Earning Date
- HHS 08-07-2025
- CTXR 08-12-2025
- Dividend Yield
- HHS N/A
- CTXR N/A
- EPS Growth
- HHS N/A
- CTXR N/A
- EPS
- HHS N/A
- CTXR N/A
- Revenue
- HHS $174,951,000.00
- CTXR N/A
- Revenue This Year
- HHS $6.54
- CTXR N/A
- Revenue Next Year
- HHS N/A
- CTXR $851.67
- P/E Ratio
- HHS N/A
- CTXR N/A
- Revenue Growth
- HHS N/A
- CTXR N/A
- 52 Week Low
- HHS $3.06
- CTXR $0.65
- 52 Week High
- HHS $7.72
- CTXR $15.25
- Technical
- Relative Strength Index (RSI)
- HHS 52.21
- CTXR 46.63
- Support Level
- HHS $3.59
- CTXR $1.23
- Resistance Level
- HHS $3.72
- CTXR $1.57
- Average True Range (ATR)
- HHS 0.13
- CTXR 0.11
- MACD
- HHS 0.01
- CTXR 0.01
- Stochastic Oscillator
- HHS 37.14
- CTXR 28.21
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.